Clinical trials: Breast Cancer, Metastatic
Metastatic Breast Cancer, Gastrointestinal Tumors
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
The purpose of this study is to find the maximum tolerated dose of the combination of two drugs. The two drugs are Sorafenib and Capecitabine. The drug Sorafenib is an approved drug which is used to treat certain cancers.
- Trial name
- NCT01640665
- Testing
- Sorafenib, Capecitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Metastatic Breast Cancer
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
GIM22-ERICA is a clinical trial investigating the efficacy of two different strategies in HER2 negative MBC treatment. The study will include MBC patients with histologically documented HER2 negative disease, who have progressed…
- Trial name
- NCT05833919
- Testing
- Eribulin Mesylate, Capecitabine
- Where
- 25 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Consorzio Oncotech
TNBC
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative…
- Trial name
- NCT07376629
- Testing
- HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxel
- Where
- 23 sites in China
- Volunteers
- 60 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Breast Cancer, Metastatic Breast Cancer
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00403130
- Testing
- Gemcitabine, Paclitaxel, Bevacizumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Albert Fisher
Breast Neoplasms, Breast Cancer
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective…
- Trial name
- NCT00284180
- Testing
- Vinflunine, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, HER2-positive Breast Cancer
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
- Trial name
- NCT07459673
- Testing
- Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor.
- Trial name
- NCT01484041
- Testing
- Dovitinib, Aromatase Inhibitors
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Georgetown University
Advanced Solid Tumor
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
- Trial name
- NCT05785741
- Testing
- DB-1310, Trastuzumab, Osimertinib
- Where
- 24 sites in United States, China
- Volunteers
- 1,000 people
- Sponsor
- DualityBio Inc.
Breast Cancer
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002937
- Testing
- paclitaxel, valspodar
- Where
- 4 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer, Brain Metastases
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain…
- Conditions
- Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT06088056
- Testing
- Combination use of SRT with T-DXd
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
This is an open-label, multi-institution, phase Ib trial that evaluates the safety and tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified…
- Trial name
- NCT03238196
- Testing
- Erdafitinib, Palbociclib, Fulvestrant
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted…
- Conditions
- Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT04692103
- Testing
- F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Lymphedema, Lymphedema Arm
Lymphovenous Anastomosis for Breast Cancer Lymphedema
This multi-center cohort study focuses on evaluating the efficacy of lymphovenous anastomosis (LVA) for treating pitting lymphedema in female breast cancer survivors.
- Conditions
- Lymphedema, Lymphedema Arm, Breast Cancer Lymphedema, Lymphedema, Secondary
- Trial name
- NCT06302361
- Testing
- Lymphovenous anastomosis (LVA)
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- Odense University Hospital
Metastatic Breast Cancer
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
The present multi-center, open-label, single-arm study aims to evaluate the efficacy and safety, quality of life and health resources utilization in postmenopausal women with hormone receptor positive breast cancer progressing…
- Trial name
- MACS2096 (NCT01626222)
- Testing
- Exemestane, Everolimus (RAD001)
- Where
- 84 sites in Germany
- Volunteers
- 301 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer, End of Life
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and…
- Trial name
- NCT05440929
- Testing
- Clinician Qualitative Interview
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Breast Neoplasm
Proton Radiation for Stage II/III Breast Cancer
The purpose of this study is to look at the rates of acute and long term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
- Trial name
- NCT01758445
- Testing
- Proton Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 220 people
- Sponsor
- Proton Collaborative Group
Healthy Participants, Breast Cancer
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
This study aims to evaluate the feasibility of using See.d instrument and SBS slides for preparation of plasma and cytological samples from whole blood.
- Trial name
- NCT06097156
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Breast Cancer
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer.
- Trial name
- NCT01777945
- Testing
- capecitabine, docetaxel
- Where
- 14 sites in Hungary
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Primary Objectives: 1. To assess the feasibility of mini-allogeneic Peripheral Blood Progenitor Cell (PBPC) transplantation in patients with recurrent or metastatic breast cancer. 2.
- Trial name
- NCT00429572
- Testing
- Fludarabine, Melphalan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.